Schering-Plough and Merck & Co. to Develop new Cholesterol Treatment
Business Review Editor
Abstract
Schering-Plough and Merck & Co. entered into agreement to develop fixed-dose ezetimibe (Zetia®) and atorvastatin (Lipitor®) combination product for lowering cholesterol.
Full Text: pdf
Add comment

This work is licensed under a Creative Commons Attribution 3.0 License.